Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
Silence Therapeutics (SLN) shares surged over 100% after Merck KGaA offered to acquire the company for $1.3B, a 130% premium. The deal, at $20 per ADS, is subject to regulatory approvals and expected to close in Q1 2027. Hedge fund interest in SLN has increased, with 24 funds holding positions in Q2. Both companies cited strategic alignment and growth prospects.
How this was made
The 30-second read
Why it matters
The acquisition premium and immediate share surge indicate strong market belief in the strategic fit, but the deal remains subject to shareholder and court approvals.
Market read
A $1.3 billion, 130% premium deal that more than doubled the target's share price, creating immediate trading opportunities.
What to watch
Potential antitrust review in Europe and the U.S. could add risk; integration challenges for the siRNA platform may affect long‑term value.
Background
Silence Therapeutics is a Nasdaq‑listed siRNA biotech; Merck KGaA is a German pharma group expanding its rare‑disease portfolio.
Ticker impact
Merck KGaA announced a $1.3 billion all‑cash acquisition of Silence Therapeutics at a 130% premium, sending SLN shares up more than 100% intraday.
modest upside as the market prices in the acquisition premium
The acquisition is newly disclosed, large‑scale, and has already moved the stock dramatically; traders can position for the short‑term price run‑up or hedge against deal risk.
Market effects
Strengthens Merck KGaA's presence in rare‑disease siRNA space, may spur M&A activity in biotech sector.
European biotech valuations could see a lift as premium deals become more common.
Large‑cap pharma investors may re‑balance exposure to specialty biotech pipelines.
Counterpoint
If regulatory hurdles delay the deal, the stock could fall sharply from the current inflated level.
Key entities
- companySilence Therapeutics
Target of the acquisition, ticker SLN.
- companyMerck KGaA
Acquirer, offering $20 per ADS.
